Furthermore, a Phase I trial of oral yeast-derived β-glucan to enhance anti-GD2 immunotherapy in resistant high-risk neuroblastoma found that a positive anti-mouse antibody response and Dectin-1 rs3901533 polymorphism are associated with better overall survival in patients, supporting Dectin-1 as a promising therapeutic target for human tumors [35]. Here, CLEC7A is linked to neuroblastoma.